Table 2.

Detailed information on patients harboring the ATM mutation

Patient number	#1	#2	#3	#4	#5	#6	#7	#8	#9	#10
Mutation	Missense mutation	Missense mutation	Missense mutation	Missense mutation	Missense mutation	Frameshift deletion	Missense mutation	Missense mutation	Frameshift insertion	Missense mutation
VAF (%)	43.01	53.22	46.3	79.92	11.8	25.88	92.49	6.45	5.08	0.369
Amino acid change	p.R2832H	p.R924O	p.K92T	p.P2974L	p.L822S	p.L2946Nfs*9	p.K92T	p.L413I	p.S28212Vfs*3	p.P260T
Sequence change	c.8495G > A	c.2771G > A	c.275A > C	c.8921C > T	c.2465 T > C	c.8835_8836delGT	c.275A > C	c.1237C > A	c.8432dupA	c.778C > A
Age, years	63	51	47	35	32	43	37	58	63	59
Sex	Male	Female	Female	Female	Male	Male	Female	Male	Male	Male
KPS	70	90	80	90	80	80	90	80	100	60
Pathology	GBM	GBM	GBM	GBM	GBM	GBM	AA, IDH-WT	AA, IDH-WT	AA, IDH-WT	AA, IDH-WT
MGMT promoter methylation	(−)	(+)	(+)	(−)	(+)	(+)	(−)	(−)	(+)	(+)
SVZ involvement	Yes	None	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Gliomatosis	No	No	Yes	Yes	No	Yes	No	Yes	Yes	Yes
Extent of resection	Subtotal	Subtotal	Partial	Subtotal	Subtotal	Subtotal	Partial	Subtotal	Partial	Subtotal
Total RT dose, Gy	60	60	60.2	60	60	60	60	60.2	60	60
PD	Yes	Yes	No	Yes	No	No	No	Yes	No	No
PD interval, months	11.6	18.9	18.0	14.4				15.4
Progression site*	Out-field	Out-field	Out-field	Out-field				Out-field
Salvage treatment	CTx	Re-RT	BSC	BSC				Re-RT
Follow-up, months	22.7	19.8	20.8	15.0	8.1	11.4	18.7	17.3	19.2	11.1
Survival	Dead	Alive	Dead	Dead	Alive	Alive	Alive	Alive	Alive	Alive

Abbreviations: VAF Variant Allele Frequency, KPS Karnofsky performance status, GBM glioblastoma, AA anaplastic astrocytoma, IDH isocitrate dehydrogenase, WT wild-type, MGMT O[6]-methylguanine-DNA methyltransferase, SVZ subventricular zone, RT radiation therapy, PD progressive disease, CTx chemotherapy, Re-RT re-irradiation, BSC best supportive care

* Progression site was defined based on relationship between radiation field and recurrence site